Education
About Us
Working with TipRanks
Follow Us
Alpha Tau Medical Ltd (DRTS)
NASDAQ:DRTS
DRTS Stock Chart & Stats
$5.84
$0.35(10.45%)
At close: 4:00 PM EST
$5.84
$0.35(10.45%)
Day’s Range― - ―
52-Week Range$2.30 - $7.89
Previous CloseN/A
Volume116.73K
Average Volume (3M)63.15K
Market Cap
$606.23M
Enterprise Value$616.40M
Total Cash (Recent Filing)$72.21M
Total Debt (Recent Filing)$13.50M
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Mar 05, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding85,264,145
10 Day Avg. Volume63,869
30 Day Avg. Volume63,150
Financial Highlights & Ratios
PEG Ratio-0.96
Price to Book (P/B)3.46
Price to Sales (P/S)0.00
P/FCF Ratio-9.84
Enterprise Value/Market Cap1.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-17.95
Forecast
1Y Price Target
$7.00Price Target Upside19.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ResultsAn 81% disease control rate and measurable tumor responses in the first-in-human pancreatic study signal promising clinical activity that could translate into meaningful benefit for patients with limited treatment options.
Manufacturing And SupplyAwarding of a radioactive material license in New Hampshire, plans for additional production sites with substantial output capacity, and U.S. manufacturing slated to begin in 2026 support the company’s readiness to scale supply for commercialization.
Regulatory ProgressSubmission of a PMA module and FDA acceptance of a modular review, together with Breakthrough Device designation and multiple IDE approvals, reflect regulatory momentum that could accelerate access if pivotal data confirm safety and effectiveness.
Bears Say
Commercialization TimelineAn adjusted U.S. commercialization timeline pushing launch expectations later increases uncertainty around near-term revenue generation and market adoption.
International LaunchA planned limited or 'soft' commercial release in Japan reduces immediate sales potential in that market and postpones a full commercial rollout.
Regulatory And Data RelianceReliance on post-marketing data to support future U.S. approval and broader launches creates additional regulatory and execution risk that could delay wider market availability.
Alpha Tau Medical Ltd News
DRTS FAQ
What was Alpha Tau Medical Ltd’s price range in the past 12 months?
Alpha Tau Medical Ltd lowest stock price was $2.30 and its highest was $7.89 in the past 12 months.
What is Alpha Tau Medical Ltd’s market cap?
Alpha Tau Medical Ltd’s market cap is $606.23M.
When is Alpha Tau Medical Ltd’s upcoming earnings report date?
Alpha Tau Medical Ltd’s upcoming earnings report date is Mar 05, 2026 which is in 24 days.
How were Alpha Tau Medical Ltd’s earnings last quarter?
Alpha Tau Medical Ltd released its earnings results on Nov 20, 2025. The company reported -$0.149 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.038.
Is Alpha Tau Medical Ltd overvalued?
According to Wall Street analysts Alpha Tau Medical Ltd’s price is currently Undervalued.
Does Alpha Tau Medical Ltd pay dividends?
Alpha Tau Medical Ltd does not currently pay dividends.
What is Alpha Tau Medical Ltd’s EPS estimate?
Alpha Tau Medical Ltd’s EPS estimate is -0.12.
How many shares outstanding does Alpha Tau Medical Ltd have?
Alpha Tau Medical Ltd has 85,264,145 shares outstanding.
What happened to Alpha Tau Medical Ltd’s price movement after its last earnings report?
Alpha Tau Medical Ltd reported an EPS of -$0.149 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 10.086%.
Which hedge fund is a major shareholder of Alpha Tau Medical Ltd?
Currently, no hedge funds are holding shares in DRTS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Tau Medical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (19.86% Upside)
$7.00 (19.86% Upside)
Blogger Sentiment
Bullish
DRTS Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.66%
12-Months-Change
Fundamentals
Return on Equity
-54.38%
Trailing 12-Months
Asset Growth
15.39%
Trailing 12-Months
Company Description
Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
DRTS Stock 12 Month Forecast
Average Price Target
$7.00
▲(19.86% Upside)
Technical Analysis
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Aura Biosciences Inc
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
―
Insiders
0.04% Mutual Funds
0.89% Other Institutional Investors
98.69% Public Companies and
Individual Investors